» Articles » PMID: 36188342

Potent Virustatic Polymer-Lipid Nanomimics Block Viral Entry and Inhibit Malaria Parasites In Vivo

Abstract

Infectious diseases continue to pose a substantial burden on global populations, requiring innovative broad-spectrum prophylactic and treatment alternatives. Here, we have designed modular synthetic polymer nanoparticles that mimic functional components of host cell membranes, yielding multivalent nanomimics that act by directly binding to varied pathogens. Nanomimic blood circulation time was prolonged by reformulating polymer-lipid hybrids. Femtomolar concentrations of the polymer nanomimics were sufficient to inhibit herpes simplex virus type 2 (HSV-2) entry into epithelial cells, while higher doses were needed against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Given their observed virustatic mode of action, the nanomimics were also tested with malaria parasite blood-stage merozoites, which lose their invasive capacity after a few minutes. Efficient inhibition of merozoite invasion of red blood cells was demonstrated both and using a preclinical rodent malaria model. We envision these nanomimics forming an adaptable platform for developing pathogen entry inhibitors and as immunomodulators, wherein nanomimic-inhibited pathogens can be secondarily targeted to sites of immune recognition.

Citing Articles

Pathogen-binding nanoparticles to inhibit host cell infection by heparan sulfate and sialic acid dependent viruses and protozoan parasites.

Najer A Smart Med. 2024; 3(2):e20230046.

PMID: 39188697 PMC: 11235646. DOI: 10.1002/SMMD.20230046.


Enhanced Antimalarial and Antisequestration Activity of Methoxybenzenesulfonate-Modified Biopolymers and Nanoparticles for Tackling Severe Malaria.

Najer A, Kim J, Saunders C, Che J, Baum J, Stevens M ACS Infect Dis. 2024; 10(2):732-745.

PMID: 38271991 PMC: 10862538. DOI: 10.1021/acsinfecdis.3c00564.


Single Particle Chemical Characterisation of Nanoformulations for Cargo Delivery.

Saunders C, de Villiers C, Stevens M AAPS J. 2023; 25(6):94.

PMID: 37783923 DOI: 10.1208/s12248-023-00855-w.


Characterization of an isolated lactase enzyme produced by ALSZ2 as a potential pharmaceutical supplement for lactose intolerance.

Amin A, Olama Z, Ali S Front Microbiol. 2023; 14:1180463.

PMID: 37779717 PMC: 10535568. DOI: 10.3389/fmicb.2023.1180463.


Revealing Population Heterogeneity in Vesicle-Based Nanomedicines Using Automated, Single Particle Raman Analysis.

Saunders C, Foote J, Wojciechowski J, Cammack A, Pedersen S, Doutch J ACS Nano. 2023; 17(12):11713-11728.

PMID: 37279338 PMC: 10311594. DOI: 10.1021/acsnano.3c02452.


References
1.
Pirrone V, Wigdahl B, Krebs F . The rise and fall of polyanionic inhibitors of the human immunodeficiency virus type 1. Antiviral Res. 2011; 90(3):168-82. DOI: 10.1016/j.antiviral.2011.03.176. View

2.
Borgheti-Cardoso L, San Anselmo M, Lantero E, Lancelot A, Serrano J, Hernandez-Ainsa S . Promising nanomaterials in the fight against malaria. J Mater Chem B. 2020; 8(41):9428-9448. DOI: 10.1039/d0tb01398f. View

3.
Triller G, Scally S, Costa G, Pissarev M, Kreschel C, Bosch A . Natural Parasite Exposure Induces Protective Human Anti-Malarial Antibodies. Immunity. 2017; 47(6):1197-1209.e10. PMC: 5738265. DOI: 10.1016/j.immuni.2017.11.007. View

4.
Sieber S, Grossen P, Bussmann J, Campbell F, Kros A, Witzigmann D . Zebrafish as a preclinical in vivo screening model for nanomedicines. Adv Drug Deliv Rev. 2019; 151-152:152-168. DOI: 10.1016/j.addr.2019.01.001. View

5.
Najer A, Wu D, Nussbaumer M, Schwertz G, Schwab A, Witschel M . An amphiphilic graft copolymer-based nanoparticle platform for reduction-responsive anticancer and antimalarial drug delivery. Nanoscale. 2016; 8(31):14858-69. DOI: 10.1039/c6nr04290b. View